CRISPR

Biotech Adam Feuerstein

STAT Plus: FDA places clinical hold on Verve Therapeutics gene-editing treatment

Biotech Ryan Cross — The Boston Globe

STAT Plus: Muscular dystrophy patient who was first in line for a custom CRISPR therapy dies

Biotech Adam Feuerstein and Damian Garde

STAT Plus: A turnaround for Editas Medicine, a CRISPR laggard, hinges on updates on key treatments

Biotech Megan Molteni

STAT Plus: A new suite of RNA-sensing tools could help scientists target cancerous cells, and much more

Biotech Jason Mast

STAT Plus: Biotech turns to new and strange viruses to overcome gene therapy’s limitations

The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein

Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0

Biotech Jason Mast

STAT Plus: After early wins, CRISPR gene editing is about to get a lot harder

Biotech Allison DeAngelis

STAT Plus: New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts

Biotech Megan Molteni

STAT Plus: Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease

The Readout LOUD Damian Garde and Adam Feuerstein

Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’

First Opinion Eric B. Kmiec

Secrecy: A demon of gene therapy’s past bedevils its future

Biotech Jason Mast

STAT Plus: Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk

In the Lab Megan Molteni

CRISPR debuted 10 years ago, in a paper hardly anyone noticed. Jennifer Doudna reflects on the DNA scissors’ first decade

Biotech Adam Feuerstein

STAT Plus: Updated study results show a CRISPR treatment for blood diseases continues to benefit patients

Biotech Adam Feuerstein

STAT Plus: A Caribou CAR-T treatment, backed by Nobel-winning science, shows blood-cancer remissions in first data reveal

First Opinion Walter G. Johnson and Diana M. Bowman

It’s time for Congress to stop blocking mitochondrial replacement therapy

Biotech Megan Molteni

STAT Plus: In the wake of big patent decision, it’s business as usual for CRISPR therapy developers

Exclusive Megan Molteni

STAT Plus: New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Biden’s plans for Covid pills, the latest vaccine data, & fighting about CRISPR

First Opinion Lee D. Cooper

Rediscovering a language of healing that doesn’t require ‘cure’

Biotech Megan Molteni

STAT Plus: 3 burning questions spurred by the big CRISPR patent ruling

Biotech Megan Molteni

STAT Plus: UC Berkeley loses CRISPR patent case, invalidating patent rights it granted gene-editing companies developing human therapies

Biotech Adam Feuerstein

STAT Plus: Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment

Biotech Megan Molteni

STAT Plus: With new trial data coming, Intellia CEO talks up the future of in vivo gene editing

Video Chat Matthew Herper

Virtual Event: CRISPR Quest

The Readout LOUD Damian Garde and Meg Tirrell

STAT Plus: Jennifer Doudna and Marty Chavez on where CRISPR meets Wall Street

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Robert Califf’s FDA return, the future of CRISPR, & another vaccine delay

In the Lab Megan Molteni

Drugs based on next-generation gene editing are moving toward the clinic faster than CRISPR 1.0